Patent examination ongoing in Korea, USA, Europe, China, India etc.
Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to Japan Patent Office on 21st July 2020. With registration of this patent, the composition of SOL-804 will be protected until 2035 in Japan. Additionally, the patent application is currently under examination in various countries, including Korea, USA, Europe, China, India, Eurasia and others.
Dyna is Bukwang’s 100% owned subsidiary which was established to focus on drug delivery and formulation. Dyna obtained exclusive global rights for the development and commercialization of SOL-804 from a Danish company, Solural Pharma, in 2016.
SOL-804 is a improved and proprietary formulated version of currently available drug for the treatment of metastatic castration-resistant prostate cancer. The proprietary formulation removes food effect and allow administration of lower dose hence SOL-804 is expected to increase patient compliance and safety profile. The phase 1 clinical study of SOL-804 in cancer patients that allow pharmacodynamic evaluation is currently under preparation.
Bukwang representative said “the registration of SOL-804’s patent in Japan acknowledges the innovative value of the technology and is an important step to advance the program into the global market.”